Top-ranked for the last 16 years, our cardiac program is led by the country’s most experienced and respected physicians and surgeons.
With 3 dedicated heart centers and a team at the forefront of medical innovation and research, our cardiac services make us the leading program in the nation for the treatment of structural heart/aortic, heart failure, and vascular disorders.
Cardiology and Cardiovascular Surgery
The Report highlights the work of NewYork-Presbyterian physicians and scientists in heart failure and transplant, structural heart disease, aortic disease, and vascular disease.
Centralized Heart Failure Management Program Using Remote Monitoring, Artificial Intelligence
Led by Nir Uriel and Gabriel Sayer, NewYork-Presbyterian developed a 5-phase approach to identify patients with worsening heart failure who may benefit from heart failure management in between clinic visits.
Management of Heart Transplant Recipients Infected With SARS-COV2
Heart transplant recipients with COVID-19 are at high risk for severe complications. The researchers, led by Nir Uriel, MD, MSc, discuss implications for the management of SARS-COV2, given the need for immunosuppression in this patient population.
Advanced Heart Failure: Pursuing Progress on Many Fronts
From remote home monitoring to the latest medical therapies, ventricular assist devices, and heart transplantation, NewYork-Presbyterian’s cardiologists and surgeons offer the most advanced medical and surgical options to patients who have many forms of advanced cardiac disease.
Extending the Reach of Transcatheter Therapies
With the great successes of TAVR, transcatheter therapies are emerging for other types of structural heart disease, including aortic regurgitation and disorders of the mitral and triscuspid valves. At the same time, studies continue underway to further enhance these procedures.
A Minimally Invasive Device for Total Aortic Arch Repair
Cardiac and vascular surgeons at NewYork-Presbyterian Hospital have come together for a groundbreaking trial to evaluate the first device for a complete aortic arch endovascular replacement available in the United States.
Novel Therapies in Electrophysiology
Patients with heart failure and patients with congenital heart disease can present with structural anomalies that make them poor candidates for traditional treatments for arrhythmias. At NewYork-Presbyterian Hospital, electrophysiologists are studying alternative methods for overcoming challenges to regulating heart rhythm in these patients.
Clinical Considerations in Prosthetic Aortic Graft Replacement
Cardiothoracic surgeons and cardiologists at NewYork-Presbyterian Hospital provide insight into proximal aortic surgery, a lifesaving procedure for patients with ascending aortic aneurysms.
Transcatheter Trials Break New Ground
Promising catheter-based treatments under evaluation in multiple clinical trials are bringing help and hope to patients with severe mitral valve and tricuspid valve disease. At the forefront of these studies are the heart teams of NewYork-Presbyterian Hospital, where transcatheter therapies are in great demand.
Left Ventricular Remodeling and Its Reversal
Heart failure specialists at NewYork-Presbyterian Hospital examine the range of therapeutic options for heart failure caused by left ventricular remodeling. Their in-depth article in Structural Heart focuses on treatments that have been successful in preventing or reversing remodeling biological and physical approaches.
TAA Repair and Coronary Surgical Practices: Cardiac Surgeons Present Compelling Research
Cardiothoracic surgeons at NewYork-Presbyterian report on new approaches to address daunting complications with open thoracoabdominal aneurysm repair and the ongoing debate on the adoption of coronary surgery as a super specialty.
Mitral Valve Disease: The Treatment Evolution Continues
NewYork-Presbyterian heart teams are spearheading the latest trials in transcatheter repair and replacement to minimize the risks and maximize the outcomes for patients with complex mitral valve disease.
At #4 in the Nation, Elevating Cardiac Care Continues
NewYork-Presbyterian/Columbia University Irving Medical Center’s renowned cardiology and cardiac surgery program is advancing the field through our groundbreaking work in TAVR, adult congenital heart disease, sports cardiology, and obestrical cardiology programs.
Dr. Nir Uriel: Elevating Progress in Advanced Heart Failure
Dr. Nir Uriel, an internationally recognized leader in heart failure, mechanical circulatory support, and heart transplantation, will oversee heart failure programs at NewYork-Presbyterian’s campuses in Manhattan, Queens, Brooklyn, and Westchester.
Noteworthy Progress in LVAD Therapy: The HeartMate3
The FDA approved the HeartMate 3™ left ventricular assist device (LVAD) as a destination therapy for patients with advanced heart failure who are not eligible for transplant, as a life-long implant.
Pursuing Progress in Pulmonary Hypertension
Among the largest programs in the world for pulmonary hypertension, the Pulmonary Hypertension Centers of NewYork-Presbyterian manage some of the most complicated and sickest patients with this rare, progressive cardiopulmonary disease.
Mitral Valve Disease: Maximizing Outcomes with Teamwork and New Technology
Cardiologists, interventional cardiologists, and cardiac surgeons at NewYork-Presbyterian bring their expertise to bear in colla¬borations that allow the details of the patient’s disease to dictate the best treatment.
TAVR Branches Out: New Refinements, Broader Indications
In the years since the first transcatheter aortic valve replacement (TAVR) was performed, the interventional cardiologists and cardiac surgeons at NewYork-Presbyterian have made inroads in device technologies and patient selection.
Adult Congenital Heart Disease Comes of Age
With the number of adult congenital heart disease patients exceeding the number of pediatric aged patients, clinicians at the Congenital Heart Center of NewYork-Presbyterian Hospital are charged with providing care for this unique patient population.
Newsletters for Medical Professionals
2021 Issue 2
2021 Issue 1
2020 Issue 1
- Merging Surgical Expertise to Uproot Cardiac Sarcomas
- A Novel Shunt Approach Shows Promise for End-Stage Pulmonary Arterial Hypertension
- Dr. Mitchell Ellkind Named President of American Heart Association
- Dr. Nir Uriel: Elevating Progress in Advanced Heart Failure
- Dr. Stephanie Mick: Spearheading Minimally Invasive Cardiac Procedures
- TAVR Marks Another Milestone
- Dr. Martin B. Leon Recognized with American College of Cardiology’s Top Honor
- Research Highlights Targeting Challenges in Cardiovascular Disease:
- Opening New Channels of Research in Heart Disease
- Ryanodine Receptor: Another Channel Implicated in Heart Disease
- Mitral Valve Disease: Maximizing Outcomes with Teamwork and New Technology
- Current Clinical Trials for Transcatheter Mitral Valve Repair
- TAVR Branches Out: New Refinements, Broader Indications